Stephen Dickson, MD
Cardiovascular Disease · Independence, MONPI 1023422474
Payments from drug & device makers
Across 482 payments — averaging $202.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$74K
- Lilly USA, LLC$12K
- Novo Nordisk$5K
- Boston Scientific$1K
- Novartis$977
- Amgen$815
- plus $3K from 33 others
What the payments were for
- Consulting fees$4,6505%
- Speaking & faculty fees$81,90084%
- Travel & lodging$2,4503%
- Food & beverage$8,7779%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 92 | $74,118 |
| Lilly USA, LLC | 11 | $12,129 |
| Novo Nordisk | 20 | $5,042 |
| Boston Scientific | 52 | $1,255 |
| Novartis | 78 | $977 |
| Amgen | 55 | $815 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $549 |
| E.r. Squibb & Sons, L.L.C. | 20 | $360 |
| Johnson & Johnson | 21 | $355 |
| Pfizer | 13 | $323 |
| Merck | 13 | $214 |
| AstraZeneca | 12 | $184 |
| Abiomed | 1 | $144 |
| Sanofi-aventis U.S. LLC | 7 | $114 |
| Vital Connect, Inc | 5 | $100 |
| Lantheus Medical Imaging, Inc. | 4 | $98 |
| Medtronic | 1 | $89 |
| Alnylam Pharmaceuticals Inc. | 5 | $85 |
| Actelion Pharmaceuticals US, Inc. | 5 | $82 |
| Bayer | 4 | $77 |
| Getinge USA Sales, LLC | 1 | $75 |
| Scpharmaceuticals Inc. | 4 | $73 |
| Amarin Pharma, Inc. | 4 | $62 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Philips North America LLC | 3 | $46 |
| Biobeat USA Inc. | 1 | $45 |
| Lemaitre Vascular, Inc. | 1 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $31 |
| Nuwellis, Inc. | 1 | $29 |
| Atricure, Inc. | 1 | $29 |
| Abbott | 1 | $25 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| Terumo Medical Corporation | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$85,108
- Ozempic$4,650
- WATCHMAN Access System$149
- Impella$144
- Watchman$117
How this compares
$97,810 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 413 | $474,015 |
| JardianceEmpagliflozin | 375 | $417,337 |
| EliquisApixaban | 282 | $304,316 |
| XareltoRivaroxaban | 132 | $127,540 |
| OzempicSemaglutide | 53 | $64,602 |
| Repatha SureclickEvolocumab | 52 | $45,203 |
| FarxigaDapagliflozin Propanediol | 37 | $29,077 |
| Repatha SyringeEvolocumab | 12 | $13,259 |
| Metoprolol Succinate | 480 | $6,536 |
| Atorvastatin Calcium | 377 | $4,612 |
| Rosuvastatin Calcium | 375 | $3,917 |
| Ezetimibe | 180 | $3,496 |
| Spironolactone | 495 | $3,317 |
| Carvedilol | 395 | $3,164 |
| Losartan Potassium | 290 | $2,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $977 | $474,015413 claims |
| Boehringer IngelheimJardiance | $74,118 | $417,337375 claims |
| PfizerEliquis | $323 | $304,316282 claims |
| Johnson & JohnsonXarelto | $355 | $127,540132 claims |
| Novo NordiskOzempic | $5,042 | $64,60253 claims |
| AstraZenecaFarxiga | $184 | $29,07737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Independence
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
- William BowenSaint Louis$726K
- Omar AlmousalliFestus$690K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.